215 related articles for article (PubMed ID: 37076993)
21. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
22. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong.
Chow VYS; Cheung WI
BMC Gastroenterol; 2024 Jan; 24(1):49. PubMed ID: 38273255
[TBL] [Abstract][Full Text] [Related]
24. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
25. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
Abdelhamed W; El-Kassas M
J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
[TBL] [Abstract][Full Text] [Related]
28. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
29. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
31. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
32. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
Kumada T; Toyoda H; Yasuda S; Ito T; Tsuji K; Fujioka S; Hiraoka A; Kariyama K; Nouso K; Ishikawa T; Tamai T; Tada T; Tanaka J
J Viral Hepat; 2022 Oct; 29(10):919-929. PubMed ID: 35790055
[TBL] [Abstract][Full Text] [Related]
33. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
34. Risk of hepatocellular carcinoma after hepatitis C virus cure.
Luna-Cuadros MA; Chen HW; Hanif H; Ali MJ; Khan MM; Lau DT
World J Gastroenterol; 2022 Jan; 28(1):96-107. PubMed ID: 35125821
[TBL] [Abstract][Full Text] [Related]
35. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
36. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
37. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
[TBL] [Abstract][Full Text] [Related]
38. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
39. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
[TBL] [Abstract][Full Text] [Related]
40. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
Ohta A; Ogawa E; Murata M; Matsumoto Y; Yamasaki S; Ikezaki H; Furusyo N
J Med Virol; 2022 Oct; 94(10):5007-5014. PubMed ID: 35652276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
